EZH2 inhibitors: take it EZy, it is all about context
Cancer discovery, 2019•AACR
Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting
cells, response rates to immune checkpoint blockade therapy have been limited. One
reason for DLBCL immune evasion is epigenetic repression instead of activation of the
antigen-presenting MHC—a dissection of mechanisms underlying this repression suggests
an opening for restoring B-cell maturation and, along the way, MHC expression as a novel
modality of cytoreducing DLBCL and simultaneously augmenting possibilities for …
cells, response rates to immune checkpoint blockade therapy have been limited. One
reason for DLBCL immune evasion is epigenetic repression instead of activation of the
antigen-presenting MHC—a dissection of mechanisms underlying this repression suggests
an opening for restoring B-cell maturation and, along the way, MHC expression as a novel
modality of cytoreducing DLBCL and simultaneously augmenting possibilities for …
Summary
Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting cells, response rates to immune checkpoint blockade therapy have been limited. One reason for DLBCL immune evasion is epigenetic repression instead of activation of the antigen-presenting MHC—a dissection of mechanisms underlying this repression suggests an opening for restoring B-cell maturation and, along the way, MHC expression as a novel modality of cytoreducing DLBCL and simultaneously augmenting possibilities for immunotherapy.
See related article by Ennishi et al., p. 546.
AACR
